Report of the ReSPECT-GBM Phase I/IIa Dose Escalation Trial of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma via Convection Enhanced Delivery (CED) & Planned Phase IIb Trial (SNO 2022) - Sep 28, 2022 - Abstract #RADT-20; Pres time: Nov 19, 2022; 04:15 PM - 04:25 PM; Location: Ballroom B; "A RP2D of 22.3mCi in 8.8mL was selected for patients with tumor size of ≤ 15mL in the planned phase 2b trial. The PIIb trial design and comparative survival data will also be presented."
P1/2 data • P2b data • Brain Cancer • Glioma • Immunology • Oncology • Solid Tumor
|
|
Andrew J. Brenner, MD.,Ph.D; William T. Phillips, MD; Ande Bao, Ph.D.; Marc Hedrick; Norman LaFrance; Joel Michalek, PhD; Toral R. Patel, MD (she/her/hers); Jeffrey S. Weinberg, MD; John Floyd, MD
|